

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Gustavo DECO et al.

Application No.:

Group Art Unit:

Filed: February 9, 2005

Examiner:

For: METHOD FOR ANALYZING EFFECTIVENESS OF PHARMACEUTICAL  
PREPARATION**INFORMATION DISCLOSURE STATEMENT**Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure provisions of 37 CFR § 1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the subject application.

## 1. Enclosures accompanying this Information Disclosure Statement are:

- 1a. ☒ Form PTO-1449.
- 1b. ☒ Copy(ies) of IDS citation(s), except for U.S. Patents and U.S. Patent Application publications.
- 1c. ☐ English language copy of a communication(s) from a foreign Patent Office or a PCT International Search Report.
- 1d. ☐ English language translation (complete, Abstract or relevant portion(s)) attached to non-English language publications as indicated on the attached Form PTO-1449.
- 1e. ☐ Explanations of Relevancy of References (ATTACHMENT 1(e), hereto) for providing a concise explanation of non-English publications.

2. ☒ In accordance with 37 CFR § 1.98, a concise explanation of what is presently understood to be the relevance of each non-English language publication is

(Check appropriate Items 2a, 2b, 2c and/or 2d)

- 2a. ☐ satisfied for the non-English language publication(s) cited on the enclosed "English language version of the search report or action which indicates the degree of relevance found by the foreign office". (See MPEP § 609, Minimum Requirements for an Information Disclosure Statement, Part A(3): Concise Explanation of Relevance, 8th Ed., Rev. 2)

- 2b. ☒ set forth in the application.
- 2c. ☐ satisfied for the non-English language publication(s) indicated on the attached PTO-1449 as having an English language translation (complete, Abstract or relevant portion(s)) attached thereto.
- 2d. ☐ enclosed as Attachment 1(e), hereto.
3. No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than search report(s) from a counterpart foreign application or a PCT International Search Report, if submitted herewith). 37 CFR §§ 1.97(g) and (h).

Respectfully submitted,

STAAS & HALSEY LLP

Dated: 2/9/05  
1201 New York Ave., N.W., Suite 700  
Washington, D.C. 20005  
Telephone: (202) 434-1500  
Facsimile: (202) 434-1501

By: Richard A. Gollhofer  
Richard A. Gollhofer  
Registration No. 31,106

FORM PTO-1449  <b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY DOCKET NO. <b>1454.1594</b>	APPLICATION NO.
		FIRST NAMED INVENTOR <b>Gustavo DECO et al.</b>	
		FILING DATE <b>February 9, 2005</b>	GROUP ART UNIT

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
----------------------	-----------------	------	------	-------	---------------	----------------

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NO.	DATE	COUNTRY	TRANSLATION YES NO	ABSTRACT
	AB				

**OTHER REFERENCES (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PP., ETC.)**

			TRANSLATION YES NO
	AC	Marc Mentis et al., "Pallidal Deep Brain Stimulation and Levodopa Infusion Have Different Effects on Functional Connectivity During Motor Performance" Neurology, vol. 56, Suppl 3, April 2001, pp. A280-A281	
	AD	Scott Grafton, et al., "Network Analysis of Motor System Connectivity in Parkinson's Disease: Modulation of Thalamocortical Interactions After Pallidotomy", Human Brain Mapping, vol. 2, 1994 pp. 44-55	
	AE	A. Feigin et al., "Effects of levodopa infusion on motor activation responses in Parkinson's disease" Neurology, vol. 59, No. 2, July 23, 2002, pp. 220-226	
	AF	A. R. McIntosh et al., "Structural Equation Modeling and Its Application to Network Analysis in Functional Brain Imaging", Human Brain Mapping, vol. 2, 1994, pp. 2-22	
	AG	Sherri Gold et al., "Functional MRI Statistical Software Packages: A Comparative Analysis", Human Brain Mapping, vol. 6, 1998, pp. 73-84	
	AH	T. W. Anderson, "Chapter 3: Estimation of Mean Vector and the Covariance of Matrix", An Introduction to Multivariate Statistical Analysis, 1994, pp. 44-57	
	AI	Samuel Kotz et al., "Cornish Fisher and Edgeworth Expansions", Encyclopedia of Statistical Sciences, vol. 2, 1982, pp. 188-193	
	AJ	Mark Cohen, "Rapid MRI and Functional Applications", Chapter 9 of Toga et al., Brain Mapping: The Methods, 1996, pp. 223-255	
	AK	Description of "fmri.pro" software from www.med.unimuenchen.de, printed September 7, 2001, 3 pages	
	AL	"Die funktionale Magnetresonanz-Tomographie (fMRI)", from www.unipublic.unizh.ch/campus/uni-news/2001/0147/fmri.html, printed September 7, 2001, 2 pages	
	AM	"Arzneimittelforschung und -entwicklung: Von der Suche nach neuen Wirkstoffen bis zu Markteinführung" from www.m-ww.de, printed August 6, 2002, 2 pages	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.